Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients

Indicators of suspected adverse reactions

Andrea Casadei Gardini, Elena Tenti, Carla Masini, Oriana Nanni, Emanuela Scarpi, Martina Valgiusti, Silvia Restuccia, Maria Laura Gallani, Simonetta Palazzini, Erica Bianchini, Silvia Menozzi, Antonio Maugeri, Dino Amadori, Martina Minguzzi, Giovanni Luca Frassineti

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Antiblastic drugs have a high number of potential side-effects. Paradoxically, according to the National Network of Pharmacovigilance, the number of reported adverse reactions to these agents is proportionally lower than that registered for non antiblastic drugs. Critical phenomena such as treatment interruptions and significant dose reductions within the first two months of use may be indicators of adverse drug reactions. The aim of the present study was to increase our knowledge of pharmacovigilance to facilitate the actions taken to improve the risk-benefit profile of cancer drugs and, consequently, their safety. This retrospective observational survey was carried out on prescriptions from 1st January 2012 to 31st December 2012. Dose reductions of more than 10% during the first 90 days of therapy were considered as a surrogate indicator of an adverse reaction. Dose interruptions during the first 60 days of therapy were taken into consideration. Of the12,472 patients 1,248 underwent a dose reduction. The drugs that most often required a dose reduction were paclitaxel and oxaliplatin (17.4% and 17.3%, respectively), docetaxel (14.8%), carboplatin (15%), fluorouracil (10.7%) and, among oral medications, capecitabine (6.9%). Of the 1896 patients treated with the same drugs, 9.7% interrupted treatment. Patients required a lower dose reduction than that reported by other authors. Around 15% of cases underwent a 30% dose reduction within three months of starting therapy, indicating a possible adverse reaction. Constant monitoring of dose prescription and continuous training of medical and nursing staff are clearly needed to increase awareness of the importance of reporting adverse events.

Original languageEnglish
Pages (from-to)40719-40724
Number of pages6
JournalOncotarget
Volume7
Issue number26
Publication statusPublished - 2016

Fingerprint

Drug Therapy
Pharmacovigilance
oxaliplatin
Pharmaceutical Preparations
docetaxel
Neoplasms
Prescriptions
Therapeutics
Nursing Staff
Carboplatin
Medical Staff
Paclitaxel
Drug-Related Side Effects and Adverse Reactions
Fluorouracil
Surveys and Questionnaires
Safety

Keywords

  • Capecitabine
  • Docetaxel
  • Oxaliplatin
  • Pathology section
  • Pharmacovigilance
  • Sorafenib

ASJC Scopus subject areas

  • Oncology

Cite this

Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients : Indicators of suspected adverse reactions. / Gardini, Andrea Casadei; Tenti, Elena; Masini, Carla; Nanni, Oriana; Scarpi, Emanuela; Valgiusti, Martina; Restuccia, Silvia; Gallani, Maria Laura; Palazzini, Simonetta; Bianchini, Erica; Menozzi, Silvia; Maugeri, Antonio; Amadori, Dino; Minguzzi, Martina; Frassineti, Giovanni Luca.

In: Oncotarget, Vol. 7, No. 26, 2016, p. 40719-40724.

Research output: Contribution to journalArticle

Gardini, AC, Tenti, E, Masini, C, Nanni, O, Scarpi, E, Valgiusti, M, Restuccia, S, Gallani, ML, Palazzini, S, Bianchini, E, Menozzi, S, Maugeri, A, Amadori, D, Minguzzi, M & Frassineti, GL 2016, 'Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: Indicators of suspected adverse reactions', Oncotarget, vol. 7, no. 26, pp. 40719-40724.
Gardini, Andrea Casadei ; Tenti, Elena ; Masini, Carla ; Nanni, Oriana ; Scarpi, Emanuela ; Valgiusti, Martina ; Restuccia, Silvia ; Gallani, Maria Laura ; Palazzini, Simonetta ; Bianchini, Erica ; Menozzi, Silvia ; Maugeri, Antonio ; Amadori, Dino ; Minguzzi, Martina ; Frassineti, Giovanni Luca. / Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients : Indicators of suspected adverse reactions. In: Oncotarget. 2016 ; Vol. 7, No. 26. pp. 40719-40724.
@article{6ae7dcc30f284c48b7ace5a1852eef66,
title = "Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: Indicators of suspected adverse reactions",
abstract = "Antiblastic drugs have a high number of potential side-effects. Paradoxically, according to the National Network of Pharmacovigilance, the number of reported adverse reactions to these agents is proportionally lower than that registered for non antiblastic drugs. Critical phenomena such as treatment interruptions and significant dose reductions within the first two months of use may be indicators of adverse drug reactions. The aim of the present study was to increase our knowledge of pharmacovigilance to facilitate the actions taken to improve the risk-benefit profile of cancer drugs and, consequently, their safety. This retrospective observational survey was carried out on prescriptions from 1st January 2012 to 31st December 2012. Dose reductions of more than 10{\%} during the first 90 days of therapy were considered as a surrogate indicator of an adverse reaction. Dose interruptions during the first 60 days of therapy were taken into consideration. Of the12,472 patients 1,248 underwent a dose reduction. The drugs that most often required a dose reduction were paclitaxel and oxaliplatin (17.4{\%} and 17.3{\%}, respectively), docetaxel (14.8{\%}), carboplatin (15{\%}), fluorouracil (10.7{\%}) and, among oral medications, capecitabine (6.9{\%}). Of the 1896 patients treated with the same drugs, 9.7{\%} interrupted treatment. Patients required a lower dose reduction than that reported by other authors. Around 15{\%} of cases underwent a 30{\%} dose reduction within three months of starting therapy, indicating a possible adverse reaction. Constant monitoring of dose prescription and continuous training of medical and nursing staff are clearly needed to increase awareness of the importance of reporting adverse events.",
keywords = "Capecitabine, Docetaxel, Oxaliplatin, Pathology section, Pharmacovigilance, Sorafenib",
author = "Gardini, {Andrea Casadei} and Elena Tenti and Carla Masini and Oriana Nanni and Emanuela Scarpi and Martina Valgiusti and Silvia Restuccia and Gallani, {Maria Laura} and Simonetta Palazzini and Erica Bianchini and Silvia Menozzi and Antonio Maugeri and Dino Amadori and Martina Minguzzi and Frassineti, {Giovanni Luca}",
year = "2016",
language = "English",
volume = "7",
pages = "40719--40724",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "26",

}

TY - JOUR

T1 - Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients

T2 - Indicators of suspected adverse reactions

AU - Gardini, Andrea Casadei

AU - Tenti, Elena

AU - Masini, Carla

AU - Nanni, Oriana

AU - Scarpi, Emanuela

AU - Valgiusti, Martina

AU - Restuccia, Silvia

AU - Gallani, Maria Laura

AU - Palazzini, Simonetta

AU - Bianchini, Erica

AU - Menozzi, Silvia

AU - Maugeri, Antonio

AU - Amadori, Dino

AU - Minguzzi, Martina

AU - Frassineti, Giovanni Luca

PY - 2016

Y1 - 2016

N2 - Antiblastic drugs have a high number of potential side-effects. Paradoxically, according to the National Network of Pharmacovigilance, the number of reported adverse reactions to these agents is proportionally lower than that registered for non antiblastic drugs. Critical phenomena such as treatment interruptions and significant dose reductions within the first two months of use may be indicators of adverse drug reactions. The aim of the present study was to increase our knowledge of pharmacovigilance to facilitate the actions taken to improve the risk-benefit profile of cancer drugs and, consequently, their safety. This retrospective observational survey was carried out on prescriptions from 1st January 2012 to 31st December 2012. Dose reductions of more than 10% during the first 90 days of therapy were considered as a surrogate indicator of an adverse reaction. Dose interruptions during the first 60 days of therapy were taken into consideration. Of the12,472 patients 1,248 underwent a dose reduction. The drugs that most often required a dose reduction were paclitaxel and oxaliplatin (17.4% and 17.3%, respectively), docetaxel (14.8%), carboplatin (15%), fluorouracil (10.7%) and, among oral medications, capecitabine (6.9%). Of the 1896 patients treated with the same drugs, 9.7% interrupted treatment. Patients required a lower dose reduction than that reported by other authors. Around 15% of cases underwent a 30% dose reduction within three months of starting therapy, indicating a possible adverse reaction. Constant monitoring of dose prescription and continuous training of medical and nursing staff are clearly needed to increase awareness of the importance of reporting adverse events.

AB - Antiblastic drugs have a high number of potential side-effects. Paradoxically, according to the National Network of Pharmacovigilance, the number of reported adverse reactions to these agents is proportionally lower than that registered for non antiblastic drugs. Critical phenomena such as treatment interruptions and significant dose reductions within the first two months of use may be indicators of adverse drug reactions. The aim of the present study was to increase our knowledge of pharmacovigilance to facilitate the actions taken to improve the risk-benefit profile of cancer drugs and, consequently, their safety. This retrospective observational survey was carried out on prescriptions from 1st January 2012 to 31st December 2012. Dose reductions of more than 10% during the first 90 days of therapy were considered as a surrogate indicator of an adverse reaction. Dose interruptions during the first 60 days of therapy were taken into consideration. Of the12,472 patients 1,248 underwent a dose reduction. The drugs that most often required a dose reduction were paclitaxel and oxaliplatin (17.4% and 17.3%, respectively), docetaxel (14.8%), carboplatin (15%), fluorouracil (10.7%) and, among oral medications, capecitabine (6.9%). Of the 1896 patients treated with the same drugs, 9.7% interrupted treatment. Patients required a lower dose reduction than that reported by other authors. Around 15% of cases underwent a 30% dose reduction within three months of starting therapy, indicating a possible adverse reaction. Constant monitoring of dose prescription and continuous training of medical and nursing staff are clearly needed to increase awareness of the importance of reporting adverse events.

KW - Capecitabine

KW - Docetaxel

KW - Oxaliplatin

KW - Pathology section

KW - Pharmacovigilance

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84983003907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983003907&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 40719

EP - 40724

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 26

ER -